-
Zelluna ASA: Second Quarter 2026 results
-
Zelluna receives Independent Data Monitoring Committee recommendation to continue patient enrolment in ZIMA-101
-
Zelluna ASA: Notice of EGM – experienced international biotech executive proposed for election to the Board and Board member steps down
-
Zelluna ASA: Invitation to Second Quarter 2026 Results Webcast Presentation
-
Zelluna ASA: New share capital registered
-
Zelluna ASA: Disclosure of large shareholding
-
Zelluna ASA: Disclosure of large shareholding
-
Zelluna ASA: Issuance of shares to Inven2 through set-off of settlement amounts under option and license agreement
-
Zelluna doses first solid tumour patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trial
-
Zelluna ASA – Grant of Share Options
